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osting by EAbstract Crohn’s disease and familial Mediterranean fever are both inﬂammatory diseases char-
acterized by similar clinical manifestations. The concurrence of the two diseases may pose a chal-
lenge to diagnosis and treatment. In this report, we present a child with familial Mediterranean
fever and undiagnosed Crohn’s disease which made him apparently resistant to colchicine therapy.
Symptoms of Crohn’s disease were masked by the resistant fever of FMF. Amelioration of symp-
toms of both diseases was achieved when treatment of both diseases were gradually introduced.
Searching of IBD in children with colchicines resistant FMF is mandatory, as both diseases have
similar symptoms and responsible genes may modify one another.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Familial Mediterranean fever (FMF) is an inherited disorder
characterized by recurrent self-limiting attacks of joint, chest
and abdominal pain associated with fever. It occurs predomi-
nantly in those of Mediterranean origin [1]. On the other hand,in Abdelghaffar Charity Cen-
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lsevierCrohn’s disease (CD) is an inﬂammatory disease of the intestines
thatmay affect any part of the gastrointestinal tract frommouth
to anus, causing a wide variety of symptoms. It primarily causes
abdominal pain, diarrhea, vomiting, fever or weight loss, but
may also cause complications outside of the gastrointestinal
tract such as skin rashes, arthritis, inﬂammation of the eye, tired-
ness, and lack of concentration [2]. Both diseases share common
clinical and biologic features; they are both inﬂammatory disor-
ders characterized by the same chronic relapsing behavior, inﬁl-
tration by neutrophils at the site of injury, and abnormal
regulation of apoptosis [3,4]. The concurrence of the two dis-
eases may pose a challenge to diagnosis and treatment.
In this report, we present a child with both FMF and CD
which made him apparently resistant to colchicine therapy.
Amelioration of symptoms of both diseases was achieved when
treatment of both diseases were gradually introduced.2. Case presentation
Our patient is an 8-year-old boy, the ﬁrst in order of birth of
ﬁrst cousin marriage presented to our clinic with resistant
100 T.Y.A. Ghaffar, S.M. ElsayedFMF. The patient history actually started at the age of one
year when he had recurrent attacks of fever and abdominal co-
lic every 45 days that progressively became more frequent.
According to the parents’ history, abdominal colic was par-
tially relieved by defection while the fever may subside sponta-
neously or with analgesics. The child was diagnosed at the age
of 3 years as FMF patient and received 1.5 g colchicines daily
for the last 5 years with no improvement. On examination (at
the age of 8 years), the patient looked pale, in agony; his
weight and height were at the 50th percentile. He had no orga-
nomegaly and his chest and heart were clinically free. CBC
showed only moderate microcytic hypochromic anaemia (hae-
moglobin was 9.6 g/dl); white blood cells and platelets were
within normal ranges. Stool examination revealed no abnor-
malities. Liver and kidney function tests showed no abnormal-
ities, ESR was 56, CRP was 4.4 mg/dl (normal: 6) and IgD
level was 69 U/ml (normal up to 100).
Abdominal ultrasound showed diffuse and extensive hyper-
peristalsis of the small intestinal loops all over the abdomen
and pelvis. They were seen collapsed with diffusely thickened
and prominent internal rugosities of the inner wall. Barium
follow-through revealed rapid transient time. Colonoscopy
revealed bossy mucosa of the ilium (follicular nodular hyper-
plasia). Duodenal and jejunal mucosal biopsies revealed
normal villous pattern with oedema and congestion of the
mucosal lumina with diffuse inﬁltration by plasma cells and
small number of lymphocytes and eosinophils. The lymphoid
aggregations in the mucosa were slightly hyperplastic causing
mild elevation of the mucosa simulating sessile polypi. Ileal
mucosal biopsy revealed picture of mild non-speciﬁc ileal
enteritis with preserved villous pattern and colonic biopsy
showed mild superﬁcial erosions. The lamina propria showed
moderate chronic inﬂammatory cellular inﬁltrate which was
mainly lymphoplasmocytic at the luminal side with occasional
neutrophils and few eosinophils with focal cryptitis. Crypts
were regular with preserved mucin production. There was focal
oedema of the lamina as well as crypt enlargement, Fig. 1.
Molecular analysis for FMF was done by sequencing of
exon 10 and exon 2 of MEFV gene on chromosome 16p13 re-
vealed compound heterozygous for M694V and M694I muta-
tions in exon 10 conﬁrming the diagnosis of FMF [5].
Considering that FMF and IBD symptoms are similar and
that GIT inﬂammation and erosions are not signs of FMF, anFigure 1 Biopsy of the ileal mucosa of the patient.association of CD was suggested. Treatment was started with
5-aminosalicylates at a dose of 50 mg/kg/day. After 3 month,
a decrease in the frequency of attacks of fever and colic was
noticed but was not satisfactory. Oral corticosteroids was
added at the dose of 1 mg/kg/day and a satisfactory improve-
ment was noticed in the form of absence of these attacks, an
improvement of appetite, weight gain and normalization of
ESR.
Gradual decrease of steroids was started till the minimal
dose that aborts that attacks (0.6 mg/kg/day) was reached.
This was given together with a maintenance dose of azathio-
prine at a dose of 2 mg/kg/day. Colchicines was gradually
introduced with starting dose of 0.25 mg/day and a maximum
dose of 1.5 mg/day and since then, all attacks subsided.
3. Discussion
Colchicine is the sole treatment of FMF. It reduces the fre-
quency of attacks and prevents amyloidosis [6]. Complete
remission is seen in about 65% of patients and partial remis-
sion is experienced in another 20–30%. Still there are 5–10%
non-responders [7]. Reasons for non-responsiveness remain a
puzzle; an abnormality in colchicines consumption by mono-
nuclear cells suggests that these patients sustain an additional
genetic defect [8].
On the other hand, some multifactorial inﬂammatory dis-
eases are more frequent in FMF patients than in the ethnically
matched general population as inﬂammatory bowel disease
[9,10]. Investigators stated that CD appears to be more preva-
lent in FMF patients and presents later than in patients with-
out FMF. FMF in patients with CD shows a higher attack
frequency and is more often complicated by amyloidosis [10].
Recently, Sari et al. reported the concurrent manifestation of
IBD and FMF in three infants (less than 6 months of age) in
whom infantile ulcerative colitis (UC) was associated with
the MEFV mutation and suggested that the onset of UC in in-
fants should prompt a search for MEFV mutations as this
association may inﬂuence the management of the disease [11].
This is similar to what occurred in our patient in whom the
attacks started very early and very severe. The ﬁndings of the
GIT biopsies and the response to 5-aminosalicylate therapy
aided to support the diagnosis of CD in our patient. It is un-
likely that these ﬁndings could be explained by FMF.
Cattan et al. suggested that the genes responsible for one
disorder could have a modifying effect on the other inﬂamma-
tory disease which was quiet evident in our patient in whom
the FMF attacks were ameliorated when CD was effectively
managed and even the fake resistant to colchicines disappeared
[9].
4. Conclusion
Searching of IBD in children with colchicines resistant FMF is
mandatory, as both diseases have similar symptoms and
responsible genes may modify one another.Acknowledgments
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